Department of Planning and Budget
2020 Fiscal Impact Statement

1. **Bill Number:** HB1651

House of Origin	☒ Introduced	☐ Substitute	☐ Engrossed
Second House	☐ In Committee	☐ Substitute	☐ Enrolled

2. **Patron:** Adams, D.M.

3. **Committee:** Public Safety

4. **Title:** Department of Corrections; hepatitis C antiviral medication.

5. **Summary:** This bill directs the Department of Corrections (DOC) to issue a Request for Proposals (RFP) to pharmaceutical manufacturers for the purchase of an unrestricted five-year supply of hepatitis C antiviral medication and any necessary ancillary services at an annual fixed rate. The bill requires the Department to report the status of the contract to the Governor and the General Assembly by November 30, 2020, and by November 30 of each year for the duration of the contract. The report must include whether the contract has lowered the DOC's hepatitis C treatment costs and inmate health outcomes resulting from the contract.

6. **Budget Amendment Necessary**: No

7. **Fiscal Impact Estimates:** Preliminary. See Item 8 below.

8. **Fiscal Implications:** Currently, the DOC is able to treat 300 Hepatitis-C-positive offenders per year. The Governor's Introduced budget includes an additional $12.6 million in FY 2021 and $14.9 million in FY 2022 to expand the number of offenders treated for Hepatitis C. This bill requires an RFP for Hepatitis C treatment drugs and necessary ancillary services and limits the cost of the subscription-based agreement to the amount DOC spent on hepatitis C treatment in the previous fiscal year.

   The RFP process must be completed before the impact of this bill can be known. Ultimately, the impact would be dependent upon when the DOC would enter into a contract and which fiscal year is used as the expenditure baseline to fully determine the fiscal impact of the legislation.

9. **Specific Agency or Political Subdivisions Affected:** Department of Corrections

10. **Technical Amendment Necessary:** None

11. **Other Comments:** None